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Houston, Texas and Detroit, Michigan 
The influence of digitalis therapy on survivors of acute 
myocardial infarction was examined in the placebo-treated 
patients from the Beta-Blocker Heart Attack Trial 
(BHAT). Two hundred fifty (13%) of the 1,921 placebo•
treated patients were receiving digitalis at the time of 
randomization. Patients receiving digitalis differed from 
those not receiving digitalis in such baseline character•
istics as age, prior history of heart failure, prior myo•
cardial infarction and angina pectoris. They also expe•
rienced a higher proportion of in-hospital complications 
including pulmonary edema, persistent hypotension, atrial 
fibrillation and heart failure in addition to a greater 
prevalence of complex ventricular premature beats. 
The total mortality rate over a mean 25 month follow•
up period for digitalis-treated patients was 20.4% com•
pared with 8.2 % for patients not receiving digitalis; the 
The use of digitalis in patients with coronary heart disease 
in general and specifically in survivors of acute myocardial 
infarction is surrounded by controversy, The dispute re•
garding its benefits and risks in patients with heart failure 
began with the original reports of its use by Withering, 
Modem studies (1-4) have added to this controversy, Dig•
italis has been demonstrated to be effective in decreasing 
the ventricular response to atrial fibrillation and until re•
cently it was the only positive inotropic agent available for 
the treatment of heart failure, Its initial salutary effect in 
patients was reported predominantly in the treatment of heart 
failure secondary to rheumatic heart disease complicated by 
atrial fibrillation, Since then, digitalis has been used 
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odds ratio was 2.87 (p < 0.05). When the mortality rates 
were adjusted for heart failure and ventricular prema•
ture beat complexity, patients receiving digitalis again 
demonstrated a higher mortality rate, although the ad•
justed odds ratio was now lower (1.70). When the pa•
tients receiving or not receiving digitalis were compared 
by a multiple logistic regression analysis adjusting for 
17 independent variables predictive of mortality, the use 
of digitalis was no longer independently predictive of 
total mortality (adjusted odds ratio 1.07). 
These data indicate that patients receiving digitalis 
had more extensive cardiovascular disease and greater 
morbidity than patients not receiving digitalis. Their 
subsequent higher mortality rate was probably related 
to these factors rather than to digitalis therapy. 
(J Am Coil CardioI1985;6:976-82) 
more widely in the treatment of heart failure due to coronary 
heart disease, A number of investigations (7,8) have shown 
it to improve contractility in the failing heart, 
Although clinical experience supports the efficacy of dig•
italis in heart failure, the drug's potential for precipitating 
life-threatening arrhythmia has raised questions about its 
lethality in patients with coronary heart disease, The poor 
prognosis of patients with heart failure is well established 
(8) and some investigators (I) have suggested that digitalis, 
the major means of treating heart failure, may actually con•
tribute to the shortened survival of these patients, It also 
has been suggested (7) that the increased incidence of ven•
tricular ectopic rhythm in patients with heart failure may be 
an expression of digitalis toxicity, However, it is difficult 
to separate these factors from one another because heart 
failure, ventricular arrhythmia and digitalis therapy are so 
intimately related. 
Study of the patients from the Beta-Blocker Heart Attack 
Trial (BHAT) who received a placebo permits evaluation 
of the effect of the use of digitalis on mortality after myo•
cardial infarction. Using these patients, it can be asked 
whether patients with myocardial infarction who were taking 
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digitalis were at an increased risk of dying, It can also be 
asked what effect digitalis therapy had on mortality after 
adjusting for the presence of heart failure and other con•
ditions, Although patients with overt heart failure with pul•
monary edema were excluded from the trial population, 
patients who had a history of heart failure or who were 
successfully treated for heart failure before randomization 
were included in the study, The trial population represents 
a relatively homogeneous population from which patients 
with severe heart failure, for whom digitalis is the only 
therapeutic option, were excluded, In the patients in the trial 
without severe heart failure, it is possible that digitalis ther•
apy may have been optional for other conditions, such as 
atrial fibrillation in addition to mild to moderate heart failure, 
Methods 
Study group. The Beta-Blocker Heart Attack Trial was 
a multicenter, placebo-controlled, double-blind trial of the 
long-term efficacy of propranolol given to postmyocardial 
infarction patients (9, 10), Overall mortality was the primary 
end point of the trial, Men and women aged 30 to 69 years 
were eligible for the study and were followed up for 12 to 
40 months (mean 25), Study subjects were obtained through 
the coronary care units of the 31 participating clinical cen•
ters, To be eligible for the trial, a patient had to have ex•
perienced an acute myocardial infarction within 5 to 21 days 
before randomization and have fulfilled certain inclusion 
and exclusion criteria specified in the protocoL Randomi•
zation and subsequent follow-up began a median of9,3 days 
after hospitalization for the acute event Of the 3,837 pa•
tients enrolled, 1,921 were randomized to the placebo group, 
the patients analyzed in this report, Because the trial in•
vestigators were studying propranolol, which can induce 
heart failure, patients judged to have severe and persistent 
heart failure by the investigator at each clinical center were 
excluded from the triaL The excluded group constituted 8% 
of the 16,400 patients eligible for enrollment Thus, the trial 
patients, including the placebo group, were not typical of 
all patients who would be given digitalis after a myocardial 
infarction, 
The patient's use of digitalis, usually as digoxin, was 
determined at baseline just before randomization, Although 
the specific reasons for the administration of digitalis were 
not obtained, the medical history of the patient at baseline 
was derived inferentially from the baseline history of heart 
failure and atrial fibrillation, A history of heart failure was 
defined as a history of heart failure before the entry myo•
cardial infarction or during the hospitalization for the in•
farction or a history of shortness of breath treated with 
digitalis or diuretic drugs, 
Electrocardiographic monitoring. Twenty-four hour 
ambulatory electrocardiographic (Holter) recordings were 
obtained before randomization in 85.4% of the patients and 
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analyzed by previously described techniques (II), In this 
report, complex ventricular arrhythmia is defined as at least 
one ventricular premature complex pair, one ventricular 
tachycardia event (three or more ventricular premature ven•
tricular complexes) or one multiform ventricular premature 
complex, 
Mortality. Total (mean 25 month) and 4 month mor•
tality rate are the end points of the present analysis, Vital 
status was not ascertained in 7 of the 1,921 patients, 
Statistics. Biostatistical analyses were carried out at the 
Coordinating Center at the University of Texas School of 
Public Health, These analyses included the use of simple 
proportional mortality rates, the Mantel-Haenszel method 
for combining evidence from 2 x 2 tables (for the adjusted 
odds ratio) and Walker-Duncan multivariate logistic regres•
sions (12), 
Results 
Clinical features (Table 1). Of the 1,921 placebo-treated 
patients, 250 (13,0%) were receiving digitalis at baseline. 
Patients receiving digitalis tended to be older than patients 
not receiving digitalis and they reported a higher frequency 
of previous medical conditions such as heart failure, prior 
myocardial infarction and angina pectoris. Proportionately 
more digitalis-treated patients experienced in-hospital com•
plications such as pulmonary edema, persistent hypotension, 
atrial fibrillation and heart failure. Furthermore, they had a 
higher prevalence of complex ventricular arrhythmias. 
Total mortality. The digitalis treatment group had a 
total mortality rate of 20.4% compared with a rate of 8.2% 
in patients not receiving digitalis. The odds ratio for this 
difference is 2.87 (p < 0.05). The cumulative mortality 
curves for those two groups are shown in Figure 1. The 
curves separate immediately, with a cumulative mortality 
rate for those receiving digitalis at baseline being consist•
ently higher than that for patients not receiving digitalis. 
Role of heart failure. Because the primary indication 
for digitalis is the treatment of heart failure, these data were 
stratified by history of the presence of heart failure (Table 
2). History of heart failure increased the mortality rates in 
both the digitalis and nondigitalis groups, although patients 
receiving digitalis were still at an increased risk of dying 
regardless of history of heart failure. The adjusted odds ratio 
for this difference is 2.0 I, and the greatest relative difference 
is in the group without a history of failure. Figure 2 shows 
the cumulative mortality curves for patients receiving and 
not receiving digitalis after adjustment for the history of 
heart failure at baseline. 
Role of ventricular arrhythmia. Because complex 
ventricular arrhythmia has been suggested as a cause of 
increased mortality in patients receiving digitalis, the data 
were also stratified by this characteristic (Table 2). Again, 
complexity of arrhythmia increased the mortality rates in 
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Table 1. Baseline Comparison of Patients Receiving and Not 
Receiving Digitalis (BHAT placebo group) 
Patients Patients Not 
Receiving Receiving 
Digitalis Digitalis 
Variable (n = 250) (n = 1,671) 
Sex (% men) 84.0 85.2 
Age (mean)(yr) 58.5 55.0 
Heart rate (mean)(beats/min) 78.2 75.4 
Diastolic blood pressure 71.8 72.4 
(mean)(mm Hg) 
Hematocrit (mean)(%) 41.4 42.0 
Medical history (%) 
Heart failure 60.0 12.9 
Prior myocardial infarction 23.6 13.2 
Angina pectoris 43.2 35.5 
Diabetes mellitus 13.2 11.1 
Social history (%) 
Employed 72.0 75.5 
Current smoker 51.6 57.8 
Medications (%) 
Antiplatelet drugs 8.4 6.5 
Diuretic drugs 45.6 13.9 
Receiving a beta-blocker before 11.6 6.1 
entry (%) 
Hospital complications (%) 
Cardiogenic shock 2.0 1.0 
Persistent hypotension 11.6 6.2 
Incomplete A V block 7.6 8.0 
Complete A V block 4.0 2.0 
Atrial fibrillation 24.5 2.9 
Ventricular tachycardia 29.7 22.3 
Ventricular fibrillation 10.4 4.4 
Pulmonary edema 10.8 1.4 
Heart failure 52.0 9.4 
Other baseline characteristics (%) 
ST depression 38.0 24.2 
Elevated lactic dehydrogenase 81.2 69.4 
Cardiomegaly (X-ray) 49.8 32.5 
Complex ventricular 49.1 36.3 
arrhythmia* 
*Defined as at least one ventricular premature complex pair, one ven•
tricular tachycardia event or one multifonn ventricular complex. A V 
atrioventricular. 
both the digitalis and nondigitalis groups, although the pa•
tients receiving digitalis were still at an increased risk of 
dying. The adjusted odds ratio is 2.37, and the relative 
difference is greatest in patients with complexity. The mor•
tality curves for the digitalis and nondigitalis groups after 
adjustment for the presence of ventricular premature com•
plexity are shown in Figure 3. 
When the data are stratified by both history of heart 
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Figure 1. Cumulative (CUM.) mortality rate during 36 months 
of follow-up study in patients receiving or not receiving digitalis 
at baseline examination. PROP. = proportion. 
failure and complexity of arrhythmia (Table 2), the relative 
difference in mortality rates between the digitalis and non•
digitalis groups narrows even further. Here the adjusted odds 
ratio is l. 70. Figure 4 shows the mortality curves after 
adjustment for both heart failure history and ventricular 
premature beat complexity. 
Digitalis and mortality. In each of the previous anal•
yses there appears to be an association between the use of 
digitalis and mortality, although the association weakened 
when the rates were adjusted for comorbidity. As noted in 
Table I, the groups receiving and not receiving digitalis 
differed in many characteristics that could have an impact 
on mortality, not just heart failure and complex ventricular 
arrhythmia. Using the Walker-Duncan multiple logistic 
regression technique, adjustment was made for digitalis and 
16 other independent variables known to be predictive of 
mortality in the placebo group (Appendix A). When these 
variables were considered, the use of digitalis was not in•
dependently predictive of total mortality. The adjusted odds 
ratio is 1.07 (p > 0.05). 
Effects of crossover in use of digitalis. The use of 
digitalis may not remain constant over time. At the 3 month 
follow-up visit, 27.4% of the patients receiving digitalis at 
baseline were no longer taking it and 8.3% of those not 
receiving digitalis at baseline were taking it (Table 3). The 
use of digitalis remained reasonably constant after the 3 
month visit. To examine the potential effect of their early 
crossover, we examined the short-term mortality rate, de•
fined as death occurring within the first 4 months after ran•
domization. The short-term mortality rate of patients re•
ceiving digitalis at baseline was compared with the rate for 
those patients not receiving digitalis, again stratified by his•
tory of heart failure and ventricular arrhythmia complexity 
(Table 4). 
Four month mortality. This analysis indicated that the 
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Table 2. Overall Mortality by Baseline Digitalis Usage, History of Heart Failure and Presence 
of Ventricular Arrhythmia Complexity* 
Patients Receiving Patients Not 
Digitalis Receiving Digitalis 
Adjusted 
Mortality Mortality Odds Odds 
No. Rate (ric) No. Rate (9<) Ratio Ratio 
Overall 250 20.4 1.671 g.2 2.87 
History of heart failure + 150 24.0 215 14.4 1.87 2.01 
History of heart failure- !OO 15.0 1,456 7.3 2.25 
Complexity + 106 27.4 517 13.0 2.53 2.37 
Complexity - 110 11.8 907 6.0 2.12 
Heart failure + , complexity + 63 31.7 79 17.7 2.16 
Heart failure - , complexity + 43 20.9 438 12.1 1.92 
Heart failure + , complexity- 60 16.7 105 13.3 1.30 1.70 
Heart failure - , complexity- 50 6.n 802 5.0 1.22 
*Defined as at least one ventricular premature complex pair. one ventricular tachycardia event or one 
multiform ventricular complex. Data are missing for 281 patients. + = present; - = absent. 
digitalis group had an unadjusted mortality rate almost three 
times greater than that of the nondigitalis group (7. 2 a~d 
2,5%, respectively, odds ratio 3,01), Although patients With 
a history of heart faiiure had a higher mortality rate t~an 
patients without this history, in each group the odds ratios 
were similar for those receiving or not receiving digitalis, 
The adjusted odds ratio is 2,55, After adjustment for both 
heart failure history and arrhythmia complexity the odds 
ratio becomes 1.91. Furthermore, when the 17 variables 
listed in Appendix A are included in a multiple logistic 
regression analysis with 4 month mortality as the end point, 
the odds ratio decreases to 1,04, 
Figure 2. Cumulative mortality rate during 36 ~onths of foll~w­
up study in patients receiving or not receiving digitalIs at baselIne 
after adjustment for the presence of heart failure at baselme. Ab•
breviations as in Figure I. 
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Discussion 
These analyses indicate the difficulty of separating, in a 
post hoc fashion, the effect of digitalis from the natural 
history of the clinical state it is used to treat. Patients re•
ceiving digitalis have many characteristics that place them 
at a greater risk of dying including, but not limited to, heart 
failure and complex arrhythmia, On the surface, digitalis 
appears to have a deleterious effect on postinfarction patients 
who have heart failure, with or without complex ventricular 
arrhythmia, However, when the numerous interactive fac•
tors bearing on cardiac mortality are controlled, the effect 
of digitalis on mortaiity rate cannot be demonstrated 
statistically, 
Figure 3. Cumulative mortality rate during 36 months of follow•
up study in patients receiving or not receiving digitalis at baseline 
after adjustment for the presence of ventricular premature beat 
complexity. Abbreviations as in Figure I. 
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Figure 4. Cumulative mortality rate during 36 months of follow•
up study in patients receiving or not receiving digitalis at baseline, 
after adjustment for the presence of both heart failure and ven•
tricular premature beat complexity. Abbreviations as in Figure I. 
Previous studies of role of digit~lis in myocardial in•
farction. The experimental data suggest that there is an 
association between cardiac glycoside intoxication and in•
creased susceptibility to the development of ventricular ar•
rhythmias in infarcted hearts (13-18). Iesaka et a1. (17), in 
an animal infarct model, demonstrated that digitalis-induced 
ventricular arrhythmia occurred at a lower dose in animals 
with infarction and that the infarcted myocardium was a 
preferential site of origin of digitalis-toxic arrhythmias. 
However, studies by Gradman et a1. (15) indicated that 
ventricular premature compl\!x frequency did not change 
with the aqministration of digitalis in patients with an ejec•
tion fraction of less than 50% and actually decreased in 
patients with a normal ejection fraction. A review of the 
existing clinical data suggests that myocardial contractility 
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Table 3. Percent of Patients Discontinuing or Maintaining 
Digitalis Therapy at Selected Follow-Up Visits 
Patients Receiving Patients Not Receiving 
Digitalis at Baseline, Digitalis at Baseline, 
Follow-Up Not Receiving It Receiving It 
Visit (mo) at Follow-Up at Follow-Up 
3 27.4 8,3 
6 29,3 9.5 
12 33.7 11.2 
24 29.8 11.3 
improves with digitalis therapy (5-7) in patients wit~ chronic 
coronary hear disease. Systemic vascular resistance, how•
ever, may increase in humans as a response to intravenous 
administration of ouabain (19). 
Moss et al. (1), studying survivors of an acute myocardial 
infarction, observed that the use of digitalis appeared to be 
related to an increased 4 month mortality rate. This increased 
mortality rate was confined particularly to those patients 
with heart failure and complex ventricular premature com•
plexes recorded during a baseline 6 hour Holter recording. 
This observation was not made in our study (Table 4). 
Bigger et a1. (5) also found an increased I year cardiac death 
rate in the digitalis-treated group even after adjusting for 
left ventricular failure and ventricular arrhythmia, an ob•
servation again not made here. Using data from the Coronary 
Artery Surgery Study, Ryan et a1. (3) found a higher long•
term (mean 4.5 years) mortality rate in patients receiving 
digitalis than in patients not receiving digitalis (18 versus 
5%). When this mortality rate was adjusted for a variety of 
clinical, hemodynamic and angiographic variables, there 
was np observed effect on mortality related to digitalis ther•
apy. Madsen et a1. (2) also observed in postmyocardial 
Table 4. Four Month Mortality by Baseline Digitalis Usage, History of Heart Failure and 
Presence of Ventricular Arrhythmia Complexity 
Patients Receiving Patients Not 
Digitalis Receiving Digitalis 
Adjusted 
Mortality Mortality Odds Odds 
No. Rate (%) No. Rate (%) Ratio Ratio 
Overall 250 7.2 1,671 2.5 3.01 
History of heart failure + 150 9.3 215 4.7 2.11 2.02 
History of heart failure - 100 4.0 1,456 2.2 1.85 
Complexity + 106 6.6 517 3.9 1.76 2.55 
Complexity - 110 6.4 907 1.5 4.33 
Heart failure + , complexity + 63 6.3 79 6.3 1.00 
Heart failure - , complexity + 43 7.0 438 3.4 2.11 
Heart failure + , complexity- 60 11.7 105 2.9 4.49 1.91 * 
Heart failure - , complexity- 50 0.0 802 1.4 
*Last two strata combined as "heart failure -, complexity + or -." Ventricular complexity data are 
missing for 281 patients. + = present; - = absent. 
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infarction patients that much of the increased mortality as•
sociated with digitalis therapy was related to other clinical 
variables. 
Comparison with previous follow-up studies. There 
are differences in the various populations used to study this 
question. Moss et al. (1) studied all patients discharged from 
coronary care units with heart failure and pulmonary conges•
tion. They defined heart failure as significant rales or pitting 
edema, or both, and pulmonary congestion and radiographic 
evidence of interstitial edema. Because all patients were 
included in their follow-up study, the subsequent 4 month 
mortality rate was 11.5% in patients receiving digitalis and 
3% in those not receiving digitalis. Similar 4 month mor•
tality rates of 13 and 5%, respectively, were observed by 
Madsen et al. (2). In the present study, however, 8% of the 
patients were excluded from the trial because of severe and 
persistent heart failure, which is a contraindication for ther•
apy with a beta-adrenergic blocking agent. The effect of 
this exclusion of higher risk patients can be seen in the 
lower 4 month mortality rate in our study: 7.2% in the 
digitalis group and 2.5% in the nondigitalis group. In gen•
eral, our patients were similar to those studied by Moss et 
al. (1) in regard to several factors related to mortality such 
as frequency of previous myocardial infarction, age and 
presence of previous angina pectoris. Pulmonary conges•
tion, however, was almost three times more common in the 
study by Moss et al. The criterion for complex ventricular 
arrhythmia was similar in the two studies, but the frequency 
of this arrhythmia was greater in our study because of the 
longer recording duration (24 hours compared with 6 hours 
in the study of Moss et al.). 
Clinical implications. Given the constraints of this type 
of analysis, using a popUlation such as our study patients 
may prove a practical approach to examining the possible 
deleterious effects of digitalis use. In patients with overt 
heart failure, the group excluded from this study, there is 
little alternative therapy to digitalis. The critical question is 
whether digitalis therapy is beneficial or deleterious in pa•
tients with mild or moderate heart failure, a group for whom 
the physician may have therapeutic options. Our retrospec•
tive data suggest that most of the increased mortality risk 
associated with digitalis therapy is due to the nature of the 
cardiac disease being treated. To actually test the risk of 
digitalis therapy in this popUlation a randomized, placebo•
controlled trial is required. Recent studies (20) on the results 
of withdrawal of digitalis in patients with heart failure in•
dicate that such a trial is feasible, particularly with the 
development of newer methods of treating heart failure. 
Appendix A 
The 17 baseline variables examined were digitalis use, history 
of heart failure, age, employment status at the time of entry myo•
cardial infarction, prior myocardial infarction, current smoking 
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statu~, beta-blocker use before myocardial infarction, complicated 
myocardial infarction, antiplatelet drug use, diabetes, cardiothor•
acic ratio, diastolic blood pressure, diuretic drug use, ST segment 
depression, elevated lactic dehydrogenase, hematocrit and com•
plexity of ventricular arrhythmia. 
Appendix B 
Principal Investigators 
Clinical Centers 
Baylor College of Medicine. Houston. TX.. Craig M. Pratt, MD; Boston 
University School of Medicine. Boston. MA. Pantel S. Vokonas, MD; 
Brown University Affiliated Ho;,pitals. Providence. RI. Robert J. Capone, 
MD; Emory University. Atlanta. GA. Robert C. Schlant, MD; Evanston 
Hospital. Evanston. IL. Gary N. Wil~er, MD; Geisinger Medical Center. 
Danville. PA. Charles A. Laubach, MD; Greater Bultimore Medical Cen•
ter. Baltimore. MD. Thaddeus E. Prout, MD; Henry Ford Hospital. De•
troit. MI. Gerald M. Breneman, MD; Kaiser Foundation Hospital. Port•
land. OR. John A. Grover, MD; Lankenau Hospital. Philadelphia. PA. 
William L. Holmes, PhD; Long Island Jewish-Hillside Medical Center. 
New Hvde Park. NY, Kul D. Chai:lda, MD; Maimonides MedIcal Center, 
Brookl;~. NY. Edgar Lichstein, MD;Medical University of South Carolina. 
Charleston. SC. Peter C. Gazes, MD; Medical College ofVirf?inid. Rich•
mond. VA. David W. Richardson, MD; Miami Heart Institute. Miami. FL. 
Frank L. Canosa, MD; Montreal Heart Institute. Montreal. Quebec. Can•
ada. Pierre A. Theroux, MD; Mt. Sinai Hospital. Minneapolis. MN. Phillip 
J. Ranheim, MD; Northwestern University Medical School. Chicaf?o. fL, 
Olga M. Haring, MD; Overlook Hospital. Summit. NJ. John J. Gregory, 
MD; Pacific Health Research Institute. HoilOlulu. HI. J. Hudson Mc•
Namara, MD; Providence Medical Center. Portland, OR. Gordon L. 
Maurice, MD; Rush-Presbyterian-St. Lukes Medical Center. Chicago. IL. 
james A. Schoenberger, MD; Rutf?ers Medical School Raritan Valley Hos•
pital. New Brunswick. NJ. Peter T. Kuo, MD; Salt Lake Clinical Research 
Foundation, Salt Lake City. UTlOf?den Research Center. Ogden. UT; in 
Salt Lake City. Allan H. Barker, MD, in Ogden. C. BasH Williams, MD; 
State University of New York at Buffalo. Buffalo. NY. Robert M. Kohn, 
MD; University a/California. Davis. Davis, CA. Nemat O. Borhani, MD; 
Universitv of California. San Francisco. San Francisco. CA. Mary Anne 
Wamowicz, MD; University of Rochester School of Medicine. Rochester. 
NY. Paul N. Yu, MD; University of Southern California. Los Angeles. 
CA. L. Julian Haywood, MD; Veterans Administration Hospital. Little 
Rock. AK. Marvin L. Murphy, MD; Veterans Administration Hospital, 
West Roxbury. MA. Kevin M. Mcintyre, MD. 
Coordinating Center 
University of Texas. Houston. TX.. C. M. Hawkins, J. D. Curb, R. P. 
Byington. 
Electrocardiography Centers 
University of Minnesota. Minneapolis. MN. k. S. Crow; Anthropo•
metries Heart Clinic. Haddonfield. NJ. J. Morgariroth. 
Central Laboratory 
Bio-Science. Van Nuys. CA. R. Ibbott. 
National Heart, Lung, and Blood Institute Project Office, 
Bethesda, MD 
c. D. Furberg, L. M. Friedman, W. T. Ftiedewald. 
Chairman of Steering Committee 
S. Goldstein, Detroit, Ml. 
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